Abstract 1087
Background
Several lines of evidence suggest that the gut microbiome represents a novel biomarker in the era of immuno-oncology. Therefore, the prospective collection of fecal samples is now routinely included in clinical trials and acts as a new challenge for research nurses. However, little is known about patient compliance in the collection process. The objective of this study was to assess enrolment and compliance rates for fecal sample collection.
Methods
Fecal samples were prospectively collected in two academic institutions, University of Montreal Hospital and Gustave Roussy Cancer Center, using the International Human Microbiome Standards SOP Version 3 in the following groups: (1) patients with advanced non-small cell lung cancer (NSCLC) amenable to immune checkpoint inhibitors and (2) patients with early-stage NSCLC or renal cell carcinoma (RCC) at a pre-operative stage. Informed and written consent were obtained by research nurses and patient baseline characteristics were collected. Upon consent, a white opaque polypropylene pot with an anaerobic generator bag was provided to the patient, along with a document to explain the self-collection technique. Enrolment (signing of consent) and compliance (returning the sample) rates were analysed using a Chi-squared method.
Results
A total of 267 patients were eligible for the study and 252 (94%) patients with a median age of 64 agreed to sign the consent form. The enrolment rate in the study reached 96% (175/183) in patients receiving immunotherapy compared to 92% (77/84) in patients with early stage cancers undergoing surgical resection who did not receive immunotherapy (p = 0.01). Overall patient compliance was 81% (204/252). Importantly, compliance was significantly higher in the pre-immunotherapy setting (94%, 164/175) versus the pre-operative group (52%, 40/77) (p = 0.01). Furthermore, regardless of the cancer stage, women (82% or 77 patients) were more compliant than men (80% or 127 patients) (p = 0.02).
Conclusions
New tools to increase compliance and assist patients in sample collection should be developed, especially for male patients diagnosed with early stage disease who are undergoing surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bertrand Routy.
Funding
Montreal Cancer Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract